A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

Beijing Chao-Yang Hospital, Capital Medical University, Beijing

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

Peking University First Hospital, Beijing

Beijing Friendship Hospital, Capital Medical University, Beijing

Peking University Shougang Hospital, Beijing

Peking University Third Hospital, Beijing

Beijing Hospital, Beijing

Beijing GoBroad Hospital, Beijing

Zhongshan Hospital, Fudan University, Shanghai

Shanghai General Hospital, Shanghai

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

Shanghai Sixth People's Hospital, Shanghai

Shanghai Changhai Hospital, Shanghai

Nanjing First Hospital, Nanjing

Jiangsu Province Hospital, Nanjing

The Second Affiliated Hospital of Soochow University, Suzhou

The First Affiliated Hospital of Soochow University, Suzhou

Taizhou People's Hospital, Taizhou

Tianjin First Central Hospital, Tianjin

The Second Hospital of Tianjin Medical University, Tianjin

Tianjin Cancer Hospital Airport Hospital, Tianjin

Zhejiang Provincial People's Hospital, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

Xiangya Hospital of Central South University, Changsha

Hunan Cancer Hospital, Changsha

The Third Xiangya Hospital of Central South University, Changsha

Wuhan Central Hospital, Wuhan

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Tongji Hospital, Tongji Medical College of HUST, Wuhan

Zhongnan Hospital of Wuhan University, Wuhan

Yichang Central People's Hospital, Yichang

Cangzhou Central Hospital, Cangzhou